Patents by Inventor Kristen Stoltz

Kristen Stoltz has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • GCN2 and perk kinase inhibitors and methods of use thereof
    Patent number: 11912668
    Abstract: Described herein are compounds, such as compounds represented by Formula I-R: and pharmaceutically acceptable salts, enantiomers, stereoisomers, and tautomers thereof, that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Grant
    Filed: November 17, 2021
    Date of Patent: February 27, 2024
    Assignee: Deciphera Pharmaceuticals, LLC
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada Al-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand Le Bourdonnec
  • GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20230382915
    Abstract: Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Application
    Filed: December 2, 2022
    Publication date: November 30, 2023
    Inventors: Yu Mi Ahn, Gada Al-Ani, Daniel L. Flynn, Salim Javed, Patrick Kearney, Bertrand LeBourdonnec, Kristen Stoltz, Jeffery Zwicker
  • Small molecules for disrupting the super elongation complex and inhibiting transcription elongation for cancer therapy
    Patent number: 11453640
    Abstract: Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
    Type: Grant
    Filed: March 21, 2019
    Date of Patent: September 27, 2022
    Assignee: Northwestern University
    Inventors: Ali Shilatifard, Kaiwei Liang, Edwin R. Smith, Gary E. Schiltz, Rama K. Mishra, Kristen Stoltz
  • GCN2 AND PERK KINASE INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20220274934
    Abstract: Described herein are compounds that are inhibitors of GCN2 kinase or PERK kinase, and methods of treating diseases, including diseases associated with GCN2 kinase or PERK kinase, with said compounds.
    Type: Application
    Filed: November 17, 2021
    Publication date: September 1, 2022
    Inventors: Daniel L. Flynn, Patrick Kearney, Jeffery Zwicker, Gada AI-Ani, Salim Javed, Yu Mi Ahn, Kristen Stoltz, Bertrand LeBourdonnec
  • SMALL MOLECULES FOR DISRUPTING THE SUPER ELONGATION COMPLEX AND INHIBITING TRANSCRIPTION ELONGATION FOR CANCER THERAPY
    Publication number: 20210094907
    Abstract: Disclosed are compounds which may be utilized to inhibit transcription by RNA Polymerase II (Pol II), and in particular to disrupt the Super Elongation Complex (SEC). The compounds may be utilized in pharmaceutical compositions and methods for treating diseases and disorders associated with the biological activity of SEC, and in particular, diseases and disorders that are associated with high levels of expression of genes whose expression is SEC-dependent and that promote, support, or otherwise are required for the disease or disorder such as cancers.
    Type: Application
    Filed: March 21, 2019
    Publication date: April 1, 2021
    Inventors: Ali Shilatifard, Kaivvei Liang, Edwin R. Smith, Gary E. Schiitz, Rama K. Mishra, Kristen Stoltz